This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00687-07v1 51/12/4489    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bradshaw, D. Articles by Geretti, A. M. Search for Related Content PubMed PubMed Citation Articles by Bradshaw, D. Articles by Geretti, A. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2007, p. 4489-4491, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00687-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Novel Drug Resistance Pattern Associated with the Mutations K70G and M184V in Human Immunodeficiency Virus Type 1 Reverse Transcriptase

Royal Free Hospital,¹ Royal Free & University College Medical School, London, United Kingdom,² Virco BVBA, Mechelen, Belgium,³ Department of HIV Medicine, North Middlesex University Hospital, London, United Kingdom⁴

Received 24 May 2007/ Returned for modification 25 July 2007/ Accepted 31 August 2007

We describe an unusual pathway of human immunodeficiency virus type 1 reverse transcriptase resistance during therapy with tenofovir-emtricitabine, characterized initially by the mutations K70E and M184V and later by K70G and M184V, with the two mutations coexisting on the same viral genome. Phenotypic resistance to lamivudine, emtricitabine, abacavir, didanosine, and tenofovir was observed, whereas susceptibility to zidovudine and stavudine was preserved.

Published ahead of print on 17 September 2007.